Developing safer MRI contrast agents that don't contain metals

Biocompatible triarylmethyl radical-based dendrimers as nonmetallic contrast agents for MRI

NIH-funded research West Virginia University · NIH-11086793

This study is working on new MRI contrast agents that are safer for people, especially those with kidney issues, by using materials that don’t contain metals, so you can get clear images without the risks linked to traditional agents.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionWest Virginia University NIH-funded
Lab location1 site (Morgantown, United States)
Project IDNIH-11086793 on NIH RePORTER

What this research studies

This research focuses on creating new types of MRI contrast agents that are biocompatible and do not contain metals, addressing safety concerns associated with traditional gadolinium-based agents. The study aims to develop triarylmethyl radical-based dendrimers that can provide effective imaging without the risks of nephrogenic systemic fibrosis or gadolinium accumulation in the body. By utilizing innovative macromolecular templates, the research seeks to enhance the stability and efficacy of these new contrast agents in clinical settings, particularly for patients with compromised kidney function.

Who could benefit from this research

Good fit: Ideal candidates for this research include patients with acute kidney failure or those at risk of kidney complications who require MRI imaging.

Not a fit: Patients with normal kidney function who can safely use traditional gadolinium-based contrast agents may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could provide a safer alternative for MRI imaging, allowing patients with kidney issues to access necessary diagnostic procedures without the associated risks of traditional contrast agents.

How similar studies have performed: While there have been advancements in metal-free MRI contrast agents, this specific approach using triarylmethyl radical-based dendrimers is relatively novel and has not been extensively tested in clinical settings.

Where this research is happening

Morgantown, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions acute kidney injuryAnimal Cancer Model
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.